Global Economic Uncertainty and Risk Aversion: The ongoing Middle East conflict and the IMF's downgraded global growth forecasts are contributing to a general 'risk-off' sentiment in the markets. This typically leads investors to withdraw capital from higher-risk assets, such as clinical-stage biotech companies like Aclaris Therapeutics, which rely heavily on investor funding for their research and development.

Inflationary Pressures and Cost of Capital: While the US economy shows job growth, persistent global inflationary pressures, influenced by factors like higher oil prices due to geopolitical tensions, can increase the operational costs for R&D and clinical trials in the biotechnology sector. This directly impacts Aclaris's expenses and its path to profitability.

Interest Rate Environment: The strong US jobs report could empower the Federal Reserve to maintain higher interest rates for a longer period. For a non-revenue-generating biotech company, a higher interest rate environment translates to a greater cost of capital for financing its extensive research and clinical development programs, potentially affecting its ability to raise funds or increasing its debt burden.